GenesisM Breaks Ground On 154,000 Square Foot Biomanufacturing Facility In Greater Boston Area

Bedford, MA - GenesisM, a joint venture between Bain Capital Real Estate ("Bain Capital") and Botanic Properties ("Botanic"), today announced the official groundbreaking of its 154,000-square-foot Class A biomanufacturing facility at 45 Crosby Drive in Bedford, Massachusetts. The groundbreaking ceremony was attended by members of the project team, town officials and representatives, and local partners in the biotech and real estate communities.

The project marks a significant step forward in addressing the critical need for purpose-built life sciences manufacturing infrastructure in the Greater Boston region. Bain Capital and Botanic formed GenesisM to create best-in-class real estate solutions tailored to the clinical and commercial production needs of life science tenants. GenesisM’s proprietary Enhanced Core design provides a robust initial build-out that reduces tenant fit-out time and capital costs, helping companies better align their manufacturing spend and scale with product maturity.

Strategically located along the Route 3 corridor and with proximity to Kendall Square’s renowned life sciences ecosystem, the Bedford facility is designed to support multiple tenants operating independently within highly regulated manufacturing suites. Each tenant will have access to dedicated infrastructure and building systems designed to meet stringent operational requirements.

"This groundbreaking marks a major milestone in the evolution of GenesisM," said Joshua Zinns, Managing Principal of Botanic Properties. "We are proud to advance our mission of delivering flexible, capital-efficient biomanufacturing facilities that help companies bring innovative therapies to market faster and more efficiently. We are particularly pleased to be able to deliver this project in Bedford, MA, which is one of the most forward-thinking communities for life science and technology companies."

The facility will feature 27-foot ceiling heights, up to 18 loading berths, 12,000 amps of power, and 40' x 40' column spacing. GenesisM’s Enhanced Core platform is designed to provide long-term operational flexibility, accelerate buildout timelines, and reduce upfront capital requirements for tenants.

Construction is currently underway, with tenant fit-out commencing as early as Q2 2026 and final core and shell delivery expected in Q3 2026. The project team includes:

• Construction Manager: Commodore Builders
• Design Architect: Perkins&Will
• MEP Engineer: BR+A Consulting Engineers
• Structural Engineer: Thornton Tomasetti
• Civil Engineer: VHB
• cGMP Peer Review: Arcadis

Construction financing for the project was provided by Barings, one of the world’s largest diversified real estate investment managers.

"The entire GenesisM team would like to show our appreciation to Barings," said Joshua Zinns during his remarks at the groundbreaking ceremony. He went on to say, "Barings has been studying and dedicating resources to the biomanufacturing sector for years, which allowed them to make an informed investment decision when the right project came along."

About GenesisM

GenesisM is a life science cGMP manufacturing brand that leverages the deep experience and global breadth of its owners to provide flexible, scalable solutions for growth stage biotech, CDMO and pharmaceutical companies, allowing end users to better align their manufacturing capital investment with drug maturity. GenesisM builds upon Bain Capital’s existing life science R&D real estate strategy (Genesis) and decades of leading experience in the Healthcare and Life Science industries, combined with Botanic Properties’ pioneering Enhanced Core design for cGMP biomanufacturing. GenesisM is focused on delivering best-in-class facilities that streamline operations with a cost-effective, infrastructure-ready approach, with the aim of adding efficiency and supporting expedited tenant growth and speed to market.

About Bain Capital Real Estate

Bain Capital Real Estate was formed in 2018 and pursues investments in often hard-to-access sectors underpinned by enduring secular trends that drive long-term demand growth for real estate assets and services. The Bain Capital Real Estate team has been executing its strategy since 2010 (formerly as a part of Harvard Management Company), having invested and committed over $9 billion of equity across multiple sectors. Bain Capital Real Estate focuses on assets where the team applies its deep industry expertise to accelerate impact and drive operational improvements. Bain Capital Real Estate’s strategy aligns with the value-added investment approach that Bain Capital pioneered and leverages the firm’s global platform and significant experience across asset classes to further bolster its insights and sourcing capabilities. Bain Capital is one of the world’s leading private investment firms with approximately $185 billion of assets under management. For more information, visit https://www.baincapitalrealestate.com/.

About Botanic Properties

Botanic Properties was founded in 2016 as a New York-based real estate investment and development firm focused on addressing the unique needs of the life science industry. Botanic has current operations in New York, Philadelphia and Boston. The Company’s methodology for deal sourcing, underwriting and project execution is rooted in a multidisciplinary approach that prioritizes bottom-up market analysis, the technical study of tenants’ MEP and programmatic requirements and continuous improvement of design solutions for industry-driven planning and space needs.

Botanic has developed an entirely differentiated approach to delivering cGMP biomanufacturing space that focuses on addressing tenant pain points, including speed to market, security, confidentiality, flexibility and affordability.

In 2023, Botanic Properties and Bain Capital Real Estate formed GenesisM, a new real estate operating platform with a mission to invest in, deliver and manage purpose-built biomanufacturing real estate. GenesisM’s initial focus has been in the Greater Boston market, given the City’s mature R&D market and substantial unmet need for clinical and commercial stage biomanufacturing space.

About Barings

Barings is a $456+ billion* global asset management firm that partners with institutional, insurance, and intermediary clients, and supports leading businesses with flexible financing solutions. The firm, a subsidiary of MassMutual, seeks to deliver excess returns by leveraging its global scale and capabilities across public and private markets in fixed income, real assets and capital solutions.

*Assets under management as of June 30, 2025